DKDanielle C. M. van der Kaay

Danielle C. M. van der Kaay

*This is an algorithmically generated author record based on publicly available information.

Danielle C. M. van der Kaay has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Growth hormone retesting for idiopathic isolated growth hormone deficiency during and after puberty: a systematic review

    by Joeri Vliegenthart, Deveney F Wols, Jan M Wit, Wichor Bramer, Edmond H H M Rings, Erica L T van Den Akker, Danielle C M van der Kaay

    Context: Idiopathic isolated growth hormone deficiency (IIGHD) is difficult to diagnose due to the day-to-day variation in growth hormone (GH) secretion and limitations of GH stimulation testing (GHST). Although recombinant human GH (rhGH) is typically continued until near adult height (NAH), many patients no longer show deficiency at that point. The optimal timing and method for retesting GH secretion remain unclear. Objective: To summarize the currently available GHSTs in children with IIGHD, with particular focus on diagnostic strategies in the peripubertal period, timing of retesting, and the role of sex steroid priming. Methods: A systematic literature search was conducted in 4 databases up to June 2025. Studies were included if they reported on GH retesting in children with IIGHD. Data were extracted on patient characteristics, GHST protocols, priming strategies, cutoff values, and reversal rates. Risk of bias was assessed using the ROBINS-I tool. Results: Thirty-one studies involving 2057 patients were included. Retesting occurred after 1–2 years of rhGH treatment, during mid-puberty, or at (N)AH, with mean reversal rates of 46.4%, 46.3%, and 69.6%, respectively. Priming with sex steroids was inconsistently applied, using testosterone in boys and ethinyl estradiol in girls. A GH peak cutoff of 7 μg/L was most commonly used, though values varied. Mid-pubertal retesting may reduce false-positive diagnoses and treatment burden. Conclusion: Retesting strategies for IIGHD should be individualized based on treatment response and pubertal development. Early retesting is advised for poor responders, while mid-puberty retesting suits most patients with normal development. Priming is recommended in older prepubertal children. Standardization of GHST protocols and long-term outcome studies are needed to optimize care and reduce overtreatment.


  • Open Access

    Growth Hormone Withdrawal in Mid-Puberty: No Impact on Near Adult Height in Adolescents With Transient Idiopathic GHD

    by Joeri Vliegenthart, Jan M Wit, Boudewijn Bakker, Annemieke M Boot, Christiaan de Bruin, Martijn J J Finken, Josine C van der Heyden, Anita C S Hokken-Koelega, Hetty J van der Kamp, Edgar G van Mil, et al.

    Context: In children with idiopathic isolated growth hormone deficiency (IIGHD), GH secretion often normalizes by near adult height (NAH). Whether recombinant human GH (rhGH) treatment can be safely discontinued earlier remains unclear. Objective: This work aimed to investigate if withdrawing rhGH treatment from mid-puberty onward had no negative effect on attained NAH in adolescents who, after retesting, were no longer GH deficient. Methods: A prospective multicenter patient preference study was conducted at pediatric endocrinology departments in multiple centers (2017-2024) with follow-up until NAH (SEENEZ GH Study). Participants included 127 adolescents (95 male, 75%) with childhood IIGHD (GH peak 1.7-10 µg/L) who tested GH sufficient (GH peak >6.7 µg/L) at mid-puberty. Forty-four continued rhGH (GHcont), 83 discontinued (GHstop). A total of 99% of patients completed the study. Intervention included rhGH treatment continuation vs discontinuation from mid-puberty until NAH. The primary outcome measure was NAH-SDS minus target height (TH)-SDS. The secondary outcome was NAH-SDS, total pubertal growth (TPG), and predicted vs attained height gain. Results: Mean (SD) NAH-SDS minus TH-SDS was −0.17 (0.60) in the GHcont and −0.18 (0.62) in the GHstop group (P = .96). Mean NAH-SDS was −0.91 (0.76) (GHcont) vs −0.78 (0.76) (GHstop) (P = .35). Mean (SD) TPG (from start of puberty) in males was 27.5 cm (7.0; GHcont) vs 25.9 cm (6.2; GHstop) (P = .25) and in females 20.5 cm (5.7; GHcont) vs 20.9 cm (7.6; GHstop) (P = .90). Predicted vs attained height gain based on the prediction model did not differ between groups. Conclusions: In adolescents with transient IIGHD, rhGH treatment can be stopped at mid-puberty. These findings support reducing rhGH treatment duration, lowering patient burden and health-care costs.


  • Open Access

    Growth hormone treatment adjusted for growth hormone sensitivity in idiopathic short stature

    by Anne R Kruijsen, Jan M Wit, Kirsten de Groote, Lauren D Punt, A S Paul van Trotsenburg, Karijn J Pijnenburg-Kleizen, Gianni Bocca, Lizanne Berkenbosch, Petra A van Setten, Hedi L Claahsen-Van der Grinten, et al.

    Objective: This study aimed to investigate the long-term growth responses to recombinant human growth hormone (rhGH) in children with idiopathic short stature (ISS), decreased insulin-like growth factor I (IGF-1) levels, and a normal stimulated GH peak, after assessing their growth hormone (GH) sensitivity using the IGF-1 generation test (IGFGT) Design: This was a retrospective descriptive case series. Methods: One hundred and twenty-nine children with height < -2.5 standard deviation score (SDS), IGF-1 < −2.0 SDS on 2 occasions, and peak GH >10 µg/L underwent an IGFGT to be categorized into normal (neurosecretory dysfunction), intermediate, or low GH sensitivity. The first group was treated with an rhGH substitution dose (0.025–0.035 mg/kg) and the others with a higher dose (0.035–0.050 mg/kg). Patients were followed for at least 1 year, with 58 patients reaching near-adult height (NAH). Prepubertal and pubertal patients were analysed separately. Results: During the first year of treatment in prepubertal patients, height increased by 0.8 ± 0.4 SDS, height velocity by 4.0 ± 2.1 cm/year, and predicted adult height (PAH) by 0.6 ± 0.7 SDS. At NAH, average height was −1.0 ± 1.0 SDS, which is 2.1 ± 0.8 SDS higher than height at start, 1.5 ± 0.8 SDS higher than PAH at start, and 0.3 ± 0.9 SDS below target height. No group differences were observed. Using the rhGH treatment prediction models from the KIGS database, patients performed better than expected for ISS and similar to patients with idiopathic isolated GH deficiency. Conclusion: Children with ISS, decreased IGF-1 levels, and a normal stimulated GH peak show a good response to rhGH treatment. The IGFGT is a useful tool for selecting this subgroup from ISS patients and optimizing rhGH dose.


  • Open Access

    Bone health in children with Angelman syndrome at the ENCORE Expertise Center

    by Karen G. C. B. Bindels-De Heus, Doesjka A. Hagenaar, Sabine E. Mous, Ilonka Dekker, Daniëlle C. M. van der Kaay, Gerthe F. Kerkhof, Ype Elgersma, Henriette A. Moll, Marie-Claire Y. de Wit

    Angelman syndrome (AS) is a rare genetic disorder due to lack of UBE3A function on chromosome 15q11.2q13 caused by a deletion, uniparental paternal disomy (UPD), imprinting center disorder (ICD), or pathological variant of the UBE3A gene. AS is characterized by developmental delay, epilepsy, and lack of speech. Although fractures are observed frequently in our clinical practice, there are few studies on bone health in AS. The aim of this study is to investigate bone health in children with AS. In this prospective cohort study, we describe bone health in 91 children with AS visiting the ENCORE Expertise Center for AS between April 2010 and December 2021. Bone health was assessed with the bone health index (BHI) in standard deviation score (SDS) measured by digital radiogrammetry of the left hand using BoneXpert software. Risk factors analyzed were age, sex, genetic subtype, epilepsy, anti-seizure medication use, mobility, body mass index (BMI), and onset of puberty. Children with AS had a mean BHI of −1.77 SDS (SD 1.4). A significantly lower BHI was found in children with a deletion (−2.24 SDS) versus non-deletion (−1.02 SDS). Other factors associated with reduced BHI-SDS were inability to walk and late onset of puberty. Children with a history of one or more fractures (22%) had a significantly lower BHI than children without fractures (−2.60 vs −1.56 SDS). Longitudinal analysis showed a significant decrease in BHI-SDS with age in all genetic subtypes.   Conclusions: Children with AS have a reduced bone health. Risk factors are deletion genotype, no independent walking, and late onset of puberty. Bone health decreased significantly with age. What is Known: • Children with neurological disorders often have a low bone health and higher risk of fractures. • Little is known about bone health in children with Angelman syndrome (AS). What is New: • Children with AS showed a reduced bone health and this was significantly associated with having a deletion, not being able to walk independently, and late onset of puberty. • Longitudinal analysis showed a significant decrease in bone health as children got older.


  • Open Access

    Hyperphagia, Growth, and Puberty in Children with Angelman Syndrome

    by Karen G. C. B. Bindels-De Heus, Doesjka A Hagenaar, Ilonka Dekker, Danielle C. M. van der Kaay, Gerthe F. Kerkhof, Encore Expertise Center For As, Ype Elgersma, Marie-Claire Y. de Wit, Sabine E. Mous, Henriette A. Moll

    Angelman Syndrome (AS) is a rare genetic disorder caused by lack of maternal UBE3A protein due to a deletion of the chromosome 15q11.2-q13 region, uniparental paternal disomy, imprinting center defect, or pathogenic variant in the UBE3A gene. Characteristics are developmental delay, epilepsy, behavioral, and sleep problems. There is some evidence for hyperphagia, shorter stature, and higher BMI compared to neurotypical children, but longitudinal studies on growth are lacking. In this study, we analyzed prospectively collected data of 145 children with AS, who visited the ENCORE Expertise Center between 2010 and 2021, with a total of 853 visits. Children showed an elevated mean score of 25 on the Dykens Hyperphagia questionnaire (range 11–55) without genotype association. Higher scores were significantly associated with higher body mass index (BMI) standard deviation scores (SDS) (p = 0.004). Mean height was −1.2 SDS (SD 1.3), mean BMI-SDS was 0.6 (SD 1.7); 43% had a BMI-SDS > 1 and 20% had a BMI-SDS > 2. Higher BMI-SDS was significantly associated with non-deletion genotype (p = 0.037) and walking independently (p = 0.023). Height SDS decreased significantly with age (p < 0.001) and BMI-SDS increased significantly with age (p < 0.001. Onset of puberty was normal. In conclusion, children with AS showed moderate hyperphagia, lower height SDS, and higher BMI-SDS compared to norm data, with increasing deviation from the norm with age. It is uncertain how loss of maternal UBE3A function may influence growth. Attention to diet, exercise, and hyperphagia from an early age is recommended to prevent obesity and associated health problems.


  • Open Access

    Computer-aided facial analysis as a tool to identify patients with Silver–Russell syndrome and Prader–Willi syndrome

    by Silvia Ciancia, Wesley J. Goedegebuure, Lionne N. Grootjen, Anita C. S. Hokken-Koelega, Gerthe F. Kerkhof, Daniëlle C. M. van der Kaay

    Genetic syndromes often show facial features that provide clues for the diagnosis. However, memorizing these features is a challenging task for clinicians. In the last years, the app Face2Gene proved to be a helpful support for the diagnosis of genetic diseases by analyzing features detected in one or more facial images of affected individuals. Our aim was to evaluate the performance of the app in patients with Silver–Russell syndrome (SRS) and Prader–Willi syndrome (PWS). We enrolled 23 pediatric patients with clinically or genetically diagnosed SRS and 29 pediatric patients with genetically confirmed PWS. One frontal photo of each patient was acquired. Top 1, top 5, and top 10 sensitivities were analyzed. Correlation with the specific genetic diagnosis was investigated. When available, photos of the same patient at different ages were compared. In the SRS group, Face2Gene showed top 1, top 5, and top 10 sensitivities of 39%, 65%, and 91%, respectively. In 41% of patients with genetically confirmed SRS, SRS was the first syndrome suggested, while in clinically diagnosed patients, SRS was suggested as top 1 in 33% of cases (p = 0.74). Face2Gene performed better in younger patients with SRS: in all patients in whom a photo taken at a younger age than the age of enrollment was available, SRS was suggested as top 1, albeit with variable degree of probability. In the PWS group, the top 1, top 5, and top 10 sensitivities were 76%, 97%, and 100%, respectively. PWS was suggested as top 1 in 83% of patients genetically diagnosed with paternal deletion of chromosome 15q11-13 and in 60% of patients presenting with maternal uniparental disomy of chromosome 15 (p = 0.17). The performance was uniform throughout the investigated age range (1–15 years).Conclusion: In addition to a thorough medical history and detailed clinical examination, the Face2Gene app can be a useful tool to support clinicians in identifying children with a potential diagnosis of SRS or PWS. What is Known:• Several genetic syndromes present typical facial features that may provide clues for the diagnosis.• Memorizing all syndromic facial characteristics is a challenging task for clinicians. What is New:• Face2Gene may represent a useful support for pediatricians for the diagnosis of genetic syndromes.• Face2Gene app can be a useful tool to integrate in the diagnostic path of patients with SRS and PWS.


  • Approach to diagnosing a pediatric patient with severe insulin resistance in low- or middle-income countries

    by van Heerwaarde Aa, Klomberg Rcw, van Ravenswaaij-Arts Cma, Ploos van Amstel Hk, A Toekoen, Jessurun F, Garg A, van der Kaay Dcm

    D.vanderkaay@erasmusmc.nl or abhimanyu.garg@utsouthwestern.edu.J Clin Endocrinol Metab 2021, 106, 3621–3633. doi: 10.1210/clinem/dgab549 Brief Summary: This expert perspective proposes that a thorough review of medical history and physical examination is generally sufficient to diagnose a child with insulin-resistant diabetes mellitus. This simple approach is especially suitable for low- or middle-income countries. This article emphasizes the role of medical history, careful physical examination, and basic laboratory investigations in making the diagnosis of severe insulin resistance. In low- and middle-income countries (LMICs), patients and families often must pay for investigations (at diagnosis or for follow up) as well as for medicines. This puts them in a tragic situation: no patient should have to choose between getting the right information and getting the right medicine. Unfortunately, most textbooks and review articles are written by pediatric endocrinologists in high-income countries (HICs) and do not take into account the scarcity of resources. The WHO List of Essential Medicines (EML) and List of Essential diagnostics (EDL) (see Paper 13.1 in this chapter) can help identify the medicines and the diagnostic tests that are most cost-effective. In addition, pediatric endocrinologists from HICs and LMICs could jointly write algorithms that highlight the most cost-effective manner to assess and treat a patient. Medical students and fellows in both HICs and LMICs would highly benefit from this approach. On a different note, the authors found an undetectable insulin concentration in a patient with severe insulin resistance. They hypothesize that “the low endogenous insulin level can be attributed to the subcutaneous insulin administration 12 hours before the measurement”. This seems unlikely, as the high doses of NPH and of human short-acting insulin administered in this insulin-resistant patient are expected to be detectable in the insulin assay. Another possibility is a technical issue disrupted the assay run. This highlights the fact that, besides their high cost, diagnostic tests need to be reliable.

  • Open Access

    Approach to Diagnosing a Pediatric Patient With Severe Insulin Resistance in Low- or Middle-income Countries

    by Alise A van Heerwaarde, Renz C W Klomberg, Conny M A van Ravenswaaij-Arts, Hans Kristian Ploos van Amstel, Aartie Toekoen, Fariza Jessurun, Abhimanyu Garg, Daniëlle C M van der Kaay

    Diabetes mellitus (DM) in children is most often caused by impaired insulin secretion (type 1 DM). In some children, the underlying mechanism for DM is increased insulin resistance, which can have different underlying causes. While the majority of these children require insulin dosages less than 2.0 U/kg/day to achieve normoglycemia, higher insulin requirements indicate severe insulin resistance. Considering the therapeutic challenges in patients with severe insulin resistance, early diagnosis of the underlying cause is essential in order to consider targeted therapies and to prevent diabetic complications. Although rare, several disorders can attribute to severe insulin resistance in pediatric patients. Most of these disorders are diagnosed through advanced diagnostic tests, which are not commonly available in low- or middle-income countries. Based on a case of DM with severe insulin resistance in a Surinamese adolescent who was later confirmed to have autosomal recessive congenital generalized lipodystrophy, type 1 (Berardinelli–Seip syndrome), we provide a systematic approach to the differential diagnosis and work-up. We show that a thorough review of medical history and physical examination generally provide sufficient information to diagnose a child with insulin-resistant DM correctly, and, therefore, our approach is especially applicable to low- or middle-income countries.


  • Central congenital hypothyroidism caused by maternal thyrotoxicosis

    by Daphne Peeters, Sandra van Gijlswijk, Ralph W. Leunissen, Danielle C.M. van der Kaay

    Central congenital hypothyroidism (CCH) is a rare and underdiagnosed disease that sometimes is caused by maternal Graves’ disease. We report a case of CCH caused by undiagnosed, initially antibody-negative maternal thyrotoxicosis with possible disruption of fetal hypothalamic-pituitary-thyroid axis maturation. In CCH, maternal thyroid disease should be considered.


  • The influence of food order on postprandial glucose levels in children with type 1 diabetes

    by Elise M Faber, Paulien M van Kampen, Agnes Clement-De Boers, Euphemia Cam Houdijk, Daniëlle Cm van der Kaay

    To evaluate the effect of the order of intake of carbohydrates, protein, and fat on postprandial glucose levels in children with type 1 diabetes (T1D). Our hypothesis was that postprandial glucose levels would be lower when fat and protein are consumed prior to carbohydrates, compared to a meal where all macronutrients are combined. A randomized, open-label, within-subject crossover study was conducted. Twenty patients aged 7 to 17 years diagnosed with T1D for >1 year consumed 2 isocaloric meals (with similar composition) in random order. In 1 meal, the protein and fat part was consumed 15 minutes prior to the carbohydrates (test meal). In the other meal, all macronutrients were consumed together (standard meal). Capillary blood glucose measurements and continuous glucose monitoring system were used to assess multiple glucose levels during a 3-hour postprandial period. Overall, mean glucose levels were 1 mmol/L lower following the test meal compared to the standard meal (9.30 ± 3.20 vs 10.24 ± 3.35 mmol/L; P < .001). No significant difference in peak glucose was found. Glucose excursions were 1.5 and 1 mmol/L lower at 30 and 120 minutes following the test meal. A reduction in the total time period in which glucose levels exceeded 10 and 12 mmol/L of 28.7 (P = .001) and 22.3 minutes (P = .004), respectively, after the test meal was found. This study shows that consumption of protein and fat prior to carbohydrates results in lower postprandial glucose levels and reduced glycemic variability in children with T1D.